about
Recombinant Newcastle disease virus as a vaccine vector for cancer therapyMechanism of dichotomy between CD8+ responses elicited by apoptotic and necrotic cellsMyeloid suppressor cells and immune modulation in lung cancerPrimer on tumor immunology and cancer immunotherapyEndoplasmic reticulum chaperones and their roles in the immunogenicity of cancer vaccinesImmunosuppressive networks in the tumour environment and their therapeutic relevanceImmunosuppressive strategies that are mediated by tumor cellsHumoral immune response against melanoma antigens induced by vaccination with cytokine gene-modified autologous tumor cells.Systemic treatment of xenografts with vaccinia virus GLV-1h68 reveals the immunologic facet of oncolytic therapy.Advances in cancer vaccine development.Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responsesAbrogation of local cancer recurrence after radiofrequency ablation by dendritic cell-based hyperthermic tumor vaccine.Cytotoxic T-lymphocyte epitope immunodominance in the control of choroid plexus tumors in simian virus 40 large T antigen transgenic mice.Immune selection in neoplasia: towards a microevolutionary model of cancer development.Effective inhibition of melanoma tumorigenesis and growth via a new complex vaccine based on NY-ESO-1-alum-polysaccharide-HH2.The role of cytokines in corneal immunopathology.Tumor regression by combined immunotherapy and hyperthermia using magnetic nanoparticles in an experimental subcutaneous murine melanoma.The aging of the 2000 and 2011 Hallmarks of Cancer reviews: a critique.Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression.Improved local and systemic anti-tumor efficacy for irreversible electroporation in immunocompetent versus immunodeficient mice.Dendritic cells: making progress with tumour regression?λ Phage nanobioparticle expressing apoptin efficiently suppress human breast carcinoma tumor growth in vivo.Cancer immunotherapy: the past, the present and the future.Histological evaluation of intratumoral myxoma virus treatment in an immunocompetent mouse model of melanoma.The danger model approach to the pathogenesis of the rheumatic diseases.Sequential gene profiling of basal cell carcinomas treated with imiquimod in a placebo-controlled study defines the requirements for tissue rejection.The immunologic aspects of poxvirus oncolytic therapyCTL-based cancer preventive/therapeutic vaccines for carcinomas: role of tumour-associated carbohydrate antigens.Gene-expression profiling in vaccine therapy and immunotherapy for cancerDendritic cell immunotherapy for breast cancer.Autologous tumor rejection in humans: trimming the myths.The tumor-draining lymph node as an immune-privileged site.Immunoepigenetics: the unseen side of cancer immunoediting.Immunogenicity of premalignant lesions is the primary cause of general cytotoxic T lymphocyte unresponsiveness.The evolution of mathematical immunology.Frequency of MART-1/MelanA and gp100/PMel17-specific T cells in tumor metastases and cultured tumor-infiltrating lymphocytes.Functional heterogeneity of vaccine-induced CD8(+) T cells.Adenosine and anergy.The 'kiss of death' by dendritic cells to cancer cells.Adoptive immunotherapy against allogeneic kidney grafts in dogs with stable hematopoietic trichimerism
P2860
Q24602728-C2BFF8EE-4C77-4539-80E3-DF3863CE8CDEQ24629263-57C52BFC-F7C0-468B-AEC6-BB20029F2B85Q26823251-63F817A8-EBFF-4EEE-9779-3331E6003994Q27001126-71154030-6A3D-4338-8193-2CA32B9C300CQ28084299-A3B4A29F-4426-4156-8B7E-6030D733D90AQ29619244-364E971C-28DB-4558-9A64-51CFE2C8F342Q29636247-4E72457C-ADD2-4407-B088-E650F6618875Q33195347-B2D6FE26-6875-405D-B288-5F954191CCBDQ33479314-DDA91161-0F89-4778-9EBF-EDB60A6786B8Q33603404-E91FEA78-7367-4FBD-B1FB-1890BC5E0D59Q33620107-04F47EE7-55C5-41F8-8279-3DFADB219E42Q33622752-66CDBFAB-94FB-4741-8B23-B24171A03570Q33815865-75EDDD99-5376-4897-AFA5-5C4DC4F1B5ACQ33948688-DA128A77-6EAE-412F-966F-4A56F1DF84E3Q33994533-F2207007-79A9-4007-94F2-B0FF343DB9A0Q34191894-3994BF71-108C-4580-88EA-34CEA8C2A04EQ34208635-26CD9372-D050-42E5-BF4E-6723F013C6ADQ34363553-7F4F38FB-6058-4107-ADFC-5E65EB2C145AQ34467878-F9BAC32F-1364-4E8F-B67B-E9E31BD390AFQ34746051-451F5F5B-B668-4F82-8D8B-65DBA98A6EFFQ34983449-8E075C19-D6E8-4C68-9BDA-6136E8AFCA1EQ35053353-772D6C4D-6956-4187-9113-F8AAF324B91AQ35083647-68706277-EC17-402D-AAB3-537FE112F048Q35317396-23AF0D2A-F619-404E-94EF-32E1312A7491Q35564107-74768949-C68C-4AD5-AE29-C8B9A7698167Q35724734-584ADBFF-C85F-41DE-B93B-AF41CF98B4B5Q36115128-B3C49629-397B-4559-8A86-AE3194A95819Q36121116-97CADD2B-6B55-41D6-9C12-29E5B9145D07Q36138329-BF96DF61-CC0C-4666-8502-14F7E84312FEQ36480998-88DDEC77-22C3-4D57-BD3D-F218511D7D7AQ36569014-F829C981-C3E6-4CF2-883B-DDF72677506EQ36593753-0075D427-C093-4A30-8228-17EA44CA3BF7Q36666346-117403B6-694E-4A19-8748-A097F8E9C86CQ36742295-0A088BCC-FC9E-4A10-A7A6-68B1FB6762F0Q36762508-A46FF360-C6B5-4685-967D-2C241163E102Q36835348-40140393-3315-4509-9B95-3772C975A4E7Q36908627-593263D8-110F-4DA2-885D-A26FFD93A294Q36922986-E5ADB9F8-6446-4745-8479-3A88BCDE1682Q36975757-5A995D12-1CEE-4B6A-A938-F0E823293DA5Q37016470-5E044161-9810-443A-A6AE-33976FD3E75B
P2860
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年学术文章
@wuu
1996年学术文章
@zh-cn
1996年学术文章
@zh-hans
1996年学术文章
@zh-my
1996年学术文章
@zh-sg
1996年學術文章
@yue
1996年學術文章
@zh
1996年學術文章
@zh-hant
name
Is cancer dangerous to the immune system?
@en
type
label
Is cancer dangerous to the immune system?
@en
prefLabel
Is cancer dangerous to the immune system?
@en
P356
P1476
Is cancer dangerous to the immune system?
@en
P2093
P304
P356
10.1006/SMIM.1996.0035
P577
1996-10-01T00:00:00Z